HPB B
HCC Study Group
Study Group Leaders
Albert Chan (Queen Mary Hospital, Hong Kong)
Parissa Tabrizian (MT. Sinai New York, USA)
TITLE: Curative resection following neoadjuvant therapy in patients with high-risk HCC features
INTRODUCTION
Recurrence following liver resection in patients with high-risk features remains high. In these circumstances treatment with neoadjuvant (TACE/Y90/Immunotherapy/SBRT/ablation) may allow downstaging and improve outcome.
OBJECTIVES
Primary objective
• Overall and disease free survival in patients undergoing neoadjuvant therapy (TACE/Y90/immunotherapy/SBRT/ablation) following resection in borderline resectable cases vs. resection upfront.
Secondary objectives
• Time to recurrence
STUDY DESIGN: Retrospective
PARTICIPANTS: International multi-center
ELIGIBILITY CRITERIA:
Inclusion criteria/ defining borderline resectable cases:
Resection candidates:
• MELD <15
• Child Pugh A or better liver function
• Unilobar disease
• No portal hypertension
• No extrahepatic disease
High-risk features/Borderline cases:
• AFP >400 ng/mL
• Infiltrative tumor
• Macrovascular invasion (segmental or lobar ipsilateral PVT or hepatic venous involvement)
• Multifocal disease
• Presence of satellite lesions
